Growing medical devices group Tissue Regenix Group PLC (LON:TRX) said DermaPure products processed through the recently-acquired CellRight Technologies facility in San Antonio, Texas, are now on sale in the US.
It follows the completion ahead of schedule of the manufacturing technical transfer.
READ: Tissue Regenix ready to kick on after year of change
The switch brings with it a number of benefits, including the ability to meet increasing demands from global sales and distribution partners.
It also improves supply chain production efficiency, and product life cycle management, while also increasing DermaPure's shelf life from two years to three.
Strategic Milestone
“This is an important strategic milestone in the Group's long-term commercial strategy and I am pleased that the operational synergies are developing as expected,” said Tissue Regenix chief executive Steve Couldwell in a statement.
“As a result we now have greater flexibility to explore new product opportunities to meet patient demand, expanding the markets we operate in with a reduced manufacturing risk profile."
DermaPure is a decellurised human skin substitute that’s used in wound care.
The company announced plans to acquire US group CellRight, a regenerative medical devices business, last July for up to £23mln.